<DOC>
	<DOCNO>NCT01038947</DOCNO>
	<brief_summary>The purpose study assess safety , pharmacokinetics pharmacodynamics single multiple intramuscular dos Uricase-PEG 20</brief_summary>
	<brief_title>Safety Efficacy Study Intramuscular Uricase-PEG 20</brief_title>
	<detailed_description>Uricase enzyme ( find mammal human ) convert poorly soluble uric acid highly soluble allantoin . Because human lack uricase , prone develop elevate level uric acid , form crystal joint soft tissue . In chronically elevate uric acid , gout may develop . In set acute rise uric acid , see example tumor lysis syndrome , uric acid crystal damage renal tubule . Uricase-PEG 20 recombinant uricase conjugate multiple PEG molecule design prolong half-life decrease immunogenicity uricase . This study characterize safety , pharmacokinetics pharmacodynamics intramuscular Uricase-PEG 20 , anticipate route administration use future clinical development gout .</detailed_description>
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>Serum uric acid &gt; 6 mg/dL ( men ) &gt; 5 mg/dL ( woman ) Clinical laboratory value within normal limit clinically significant Women menopausal perimenopausal Prior exposure uricase History severe allergic reaction , allergy PEG pegylated product G6PD catalase deficiency Medical condition may interfere ability complete study ( e.g. , uncontrolled diabetes hypertension , congestive heart failure NYHA Class III IV , history myocardial infarction , immunosuppression , pregnancy )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>